

## References

### R-73

1. Agazaryan N, Tenn S, Chow P, et al. Volumetric modulated arc therapy treatment protocol for hypo-fractionated stereotactic body radiotherapy for localized prostate cancer. *Int J Clin Oncol Biol Phys*. 2010;78(3):S844. Abstract 3431.
2. Aluwini S, van Rooji P, Hoogeman M, et al. CyberKnife® stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: early experience, feasibility, and tolerance. *J Endourol*. 2010;24(5):865-869.
3. ASTRO Model Policies – Stereotactic Body Radiation Therapy (SBRT) Approved 8-2-10. Updated 4-17-13. Accessed July 30, 2017.
4. Boike TP, Lotan Y, Cho LC, et al. Phase I dose-escalation study of stereotactic body radiation therapy for low-and intermediate-risk prostate cancer. *J Clin Oncol*. 2011;29(15):2020-2026.
5. Bolzicco G, Favretto MS, Scremin E, et al. Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results. *Technol Cancer Res Treat*. 2010;9(5):473-477.
6. Buyyounski MK, Price RA, Harris EER, et al. Stereotactic body radiotherapy for primary management of early stage, low- to intermediate-risk prostate cancer: Report of the ASTRO Emerging Technology Committee. *Int J Radiat Oncol Biol Phys*. 2010;76(5):1297-1304.
7. Coakley FV, Oto A, Alexander LF, et al. ACR Appropriateness Criteria®. Prostate cancer—pretreatment detection, staging, and surveillance. Date of origin: 1995. Last review date: 2016.
8. Copp H, Bissonette EA, Theodorescu D. Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer. *Urology*. 2005;65(6):1146-1151.
9. D'Amico AV, Cote K, Loffredo M, et al. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer *J Clin Oncol*. 2002;20(23):4567-4573.
10. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. *JAMA*. 1998;280(11):969-974.
11. Davis BJ, Taira AV, Nguyen PL, et al. ACR Appropriateness Criteria®. Permanent source brachytherapy for prostate cancer. Date of origin: 1996. Last review date: 2016.
12. Demanes DJ, Rodriguez RR, Schour L, et al. High-dose- rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. *Int J Radiat Oncol Biol Phys*. 2005;61(5):1306-1316.
13. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. *Radiation Oncology*. 2011;6(3).
14. Friedland JL, Freeman DE, Masterson-McGary ME, et al. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. *Technol Cancer Res Treat*. 2009;8(5):387-392.
15. Fuller DB, Mardirossian G, Wong D, et al. Prospective evaluation of stereotactic body radiotherapy for low- and intermediate-risk prostate cancer: emulating high-dose-rate brachytherapy dose distribution. *Int J Radiat Oncol Biol Phys*. 2012;84(3):S149.

16. Galalae RM, Martinez A, Mate T, et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. *Int J Radiat Oncol Biol Phys*. 2004;58(4):1048-1055.
17. Gustafson GS, Nguyen PL, Assimos DG, et al. ACR Appropriateness Criteria®. Prostatectomy irradiation in prostate cancer. Date of origin: 1996. Last review date: 2014.
18. Hossain S, Xia P, Huang K, et al. Dose gradient near target–normal structure interface for nonisocentric CyberKnife® and isocentric intensity-modulated body radiotherapy for prostate cancer. *Int J Radiat Oncol Biol Phys*. 2010;78(1):58-63.
19. Hsu ICJ, Yamada Y, Assimos DG, et al. ACR Appropriateness Criteria®. High-dose-rate brachytherapy for prostate cancer. Date of origin: 2013.
20. Jabbari S, Weinberg VK, Kaprealian T, et al. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. *Int J Radiat Oncol Biol Phys*. 2012;82(1):228-234.
21. Kang JK, Cho CK, Choi CW, et al. Image-guided stereotactic body radiation therapy for localized prostate cancer. *Tumori*. 2011;97(1):43-48.
22. Katz AJ. CyberKnife® Radiosurgery for Prostate Cancer. *Technol Cancer Res Treat*. 2010;9(5):463-472.
23. Katz AJ and Kang J. Quality of life and toxicity after SBRT for organ-confined prostate, a 7-year study. *Front Oncol*. 2014;4(31):1-6.
24. Katz AJ and Kang J. Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study. *Radiation Oncol*. 2014;9(1):1-10.
25. Katz AJ, Santoro M. Quality of life and efficacy for stereotactic body radiotherapy for treatment of organ confined prostate cancer. *Int J Radiat Oncol Biol Phys*. 2010;78(3):S58.
26. Katz AJ, Santoro M, Ashley R, et al. Stereotactic body radiotherapy for organ-confined prostate cancer. *BMC Urology*. 2010;10:1.
27. King CR, Brooks JD, Gill H, et al. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. *Int J Radiat Oncol Biol Phys*. 2012;82(2):877-882.
28. King CR, Brooks JD, Gill H, et al. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. *Int J Radiat Oncol Biol Phys*. 2009;73:1043-1048.
29. King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. *Radiation Oncol*. 2013;109(2):217-221.
30. Lin Y-W, Lin L-C, and Lin K-L. The early result of whole pelvic radiotherapy and stereotactic body radiotherapy boost for high-risk localized prostate cancer. *Front Oncol*. 2014;4(278):1-8.
31. Michalski J, Pisansky TM, Lawton CA, et al. Prostate cancer (chapter 51) In: Gunderson L, Tepper J, editors. *Clinical Radiation Oncology*. 3. Philadelphia, PA: Churchill Livingstone; 2012. 1037-1097.
32. Mantz CA, Fernandez E, Zucker I, et al. A phase II trial of real-time target tracking SBRT for low-risk prostate cancer utilizing the Calypso 4D localization system: patient reported health-related quality of life and toxicity outcomes. *Int J Radiat Oncol Biol Phys*. 2010;78(3):S57-S58.
33. Martinez AA, Gustafson G, Gonzalez J, et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. *Int J Radiat Oncol Biol Phys*. 2002;53(2):316-327.

34. Martinez A, Gonzalez J, Spencer W, et al. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. *J Urol.* 2003;169(3):974-979.
35. McLaughlin PW, Liss, AL, Nguyen PL, et al. ACR Appropriateness Criteria®. Locally advanced (high-risk) prostate cancer. Date of origin: 1996. Last review date: 2016.
36. Meier R, Beckman A, Kaplan I, et al. Stereotactic radiotherapy for organ-confined prostate cancer: early toxicity and quality of life outcomes from a multi-institutional trial. *Int J Radiat Oncol Biol Phys.* 2010;78(3):S57. Abstract # 120.
37. Meier R, Mark R, St. Royal L, et al. Postoperative radiation therapy after radical prostatectomy for prostate carcinoma. *Cancer.* 1992; 70(7):1960-1966.
38. Merrick GS, Wallner KE, Butler WM. Permanent interstitial brachytherapy in the management of carcinoma of the prostate gland. *J Urol.* 2003;169(5):1643-1652.
39. Merrick GS, Wallner KE, Butler WM. Minimizing prostate brachytherapy-related morbidity. *Urology.* 2003;62(5):786-792.
40. Mroz P, Martin JM, DiPetrillo TA, et al. Analysis of potential cost benefits using reported hypofractionated radiation therapy regimens in prostate cancer in the United States. *Int J Radiat Oncol Biol Phys.* 2010;78(3):S341-S342.
41. National Comprehensive Cancer Network (NCCN) Guidelines Version 2. 2018 – March 8, 2018. Prostate Cancer.
42. Nguyen P, Aizer A, Davis BJ, et al. ACR Appropriateness Criteria® Definitive external-beam irradiation in state T1 and T2 prostate cancer. Date of origin: 1996. Last review date: 2013.
43. Pham HT, Song G, Badiozamani K, et al. Five-year outcome of stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP) for patients with low-risk prostate cancer. *Int J Radiat Oncol Biol Phys.* 2010;78(3):S58. Abstract 122.
44. Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. *J Clin Oncol.* 2005;23(6):1192-1199.
45. Stock RG, Cahlon O, Cesaretti JA, et al. Combined modality treatment in the management of high-risk prostate cancer. *Int J Radiat Oncol Biol Phys.* 2004;59(5):1352-1359.
46. Townsend NC, Huth BJ, Ding W, et al. Acute toxicity after Cyberknife-delivered hypofractionated radiotherapy for treatment of prostate cancer. *Am J Clin Oncol.* 2011;34(1):6-10.
47. Trabulsi EJ, Valicenti RK, Hanlon AL, et al. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for PT3/4N0 prostate cancer. *Urol.* 2008;72(6):1298-1302.
48. Van der Kwast TH, Bolla M, Poppel HV, et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy EORTC 22911. *J Clin Oncol.* 2007;25(27):4178-4186.
49. Wiegner EA, King CR. Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial. *Int J Radiat Oncol Biol Phys.* 2010;78(2):442-448.
50. Yu JB, Soulos PR, Herrin J et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. *J Natl Cancer Inst.* 2013;105(1):25-32.
51. Zaorsky NG, Showalter TN, Ezzell GA, et al. ACR Appropriateness Criteria®. External beam radiation treatment planning for clinically localized prostate cancer. Date of origin: 1996. Last review date: 2011.